Interstitial Cystitis
Return to Library
|
Free Interstitial Cystitis Articles |
|
|
|
|
Study findings from G.Y. Wong et al broaden understanding of clinical trial research
2009 JUN 22 - (NewsRx.com) -- A report, 'Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks,' is newly published data in Brain Research Reviews. "The vanilloid receptor TRPV1 is a homotetrameric, non-selective cation channel abundantly expressed in the nociceptors (c-fibers). TRPV1 is considered as a highly validated pain target because, i) its agonists such as capsaicin cause desensitization of TRPV1 channels that relieves pain behaviors in preclinical species, and ii) its antagonists relieve pain behaviors in rodent models of inflammation, osteoarthritis, and cancer," scientists in the United States report. "Hence, both agonists and antagonists of TRPV1 are being evaluated as potential analgesics in clinical trials. Clinical trial results of TRPV1 agonists such as resiniferatoxin in interstitial cystitis, NGX 4010 in post-herpetic neuralgia, and 4975 (Adlea) in osteoarthritis, bunionectomy, and Morton's neuroma have been reported. Similarly, clinical trial results of TRPV1 antagonists such as SB-705498 and AMG 517 have also been published recently. Overall, some molecules (e.g., capsaicin) demonstrated potential analgesia in certain conditions (postsurgical pain, postherpetic neuralgia, pain in diabetic neuropathy, osteoarthritis, bunionectomy, and Morton's neuroma), whereas others fell out of the clinic due to on-target liabilities or failed to demonstrate efficacy," wrote G.Y. Wong and colleagues, . The researchers concluded: "This review summarizes recent advances and setbacks of TRPV1 agonists and antagonists in the clinic and predicts future directions." Wong and colleagues published their study in Brain Research Reviews (Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Research Reviews, 2009;60(1):267-77). For more information, contact G.Y. Wong, Clinical Research, Anesiva, South San Francisco, CA 94080 USA.. Publisher contact information for the journal Brain Research Reviews is: Oxford University Press, Great Clarendon St., Oxford OX2 6DP, England. Keywords: United States, South San Francisco, Analgesia, Behavior, Brain Research, Cancer, Clinical Trial Research, Clinical Trials, Inflammation, Interstitial Cystitis, Neuralgia, Oncology, Osteoarthritis, Pain Medicine, Pre-Trials Research, Therapy, Treatment. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2009, Pain & Central Nervous System Week via NewsRx.com.
|
